Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
New York, May 31, 2023 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced several CAPLYTA data presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held in Miami, May 30 – June 2, 2023.
The analyses presented at the ASCP Annual Meeting demonstrated the efficacy and safety of CAPLYTA in the treatment of central nervous system disorders. CAPLYTA is an FDA-approved medication for the treatment of schizophrenia in adults, and these data presentations further showcase its potential in addressing the unmet medical needs of patients with CNS disorders.
Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, commented on the significance of the data presentations, stating, “We are pleased to share these findings with the scientific community at the ASCP Annual Meeting. The data reinforce CAPLYTA’s role as a valuable treatment option for individuals living with CNS disorders.”
Effect on Individuals:
For individuals struggling with central nervous system disorders, the data presentations at the ASCP Annual Meeting offer hope for improved treatment outcomes. CAPLYTA’s efficacy and safety profile provide reassurance for patients and healthcare providers alike, offering a potential solution to the challenges posed by these complex conditions.
Effect on the World:
The advancements in CNS disorder treatments showcased at the ASCP Annual Meeting have the potential to positively impact global healthcare. By expanding our understanding of these conditions and presenting innovative treatment options like CAPLYTA, the medical community can work towards improving outcomes for patients worldwide.
Conclusion:
The CAPLYTA data presentations at the ASCP Annual Meeting mark a significant milestone in the field of central nervous system therapeutics. With a focus on efficacy, safety, and innovation, Intra-Cellular Therapies continues to lead the way in developing solutions for individuals living with CNS disorders, shaping a brighter future for both patients and the global healthcare landscape.
